Tenofovir Disoproxil Fumarate in Patients with HIV and Lamivudine-Resistant Hepatitis B Virus

Abstract

To the Editor: Mutations in the YMDD (tyrosine, methionine, aspartate, aspartate) motif of the DNA polymerase resulting in phenotypic hepatitis B virus (HBV) resistance to lamivudine monotherapy have been observed after two years in 50 percent of patients coinfected with the human immunodeficiency virus (HIV).1 Adefovir dipivoxil has been shown to be effective for lamivudine-resistant HBV infection in HIV-coinfected patients.2 Tenofovir disoproxil fumarate, a nucleotide reverse-transcriptase inhibitor, is active against HIV and has in vitro activity against wild-type and lamivudine-resistant HBV.3,4 We examined the efficacy and safety of tenofovir disoproxil fumarate, at a dose of 300 mg given once . . .